GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » PB Ratio

ALX Oncology Holdings (ALX Oncology Holdings) PB Ratio : 4.37 (As of May. 09, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ALX Oncology Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-09), ALX Oncology Holdings's share price is $16.61. ALX Oncology Holdings's Book Value per Share for the quarter that ended in Dec. 2023 was $3.80. Hence, ALX Oncology Holdings's PB Ratio of today is 4.37.

The historical rank and industry rank for ALX Oncology Holdings's PB Ratio or its related term are showing as below:

ALXO' s PB Ratio Range Over the Past 10 Years
Min: 0.41   Med: 1.38   Max: 13.05
Current: 4.37

During the past 6 years, ALX Oncology Holdings's highest PB Ratio was 13.05. The lowest was 0.41. And the median was 1.38.

ALXO's PB Ratio is ranked worse than
70% of 1310 companies
in the Biotechnology industry
Industry Median: 2.5 vs ALXO: 4.37

During the past 12 months, ALX Oncology Holdings's average Book Value Per Share Growth Rate was -41.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -29.40% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of ALX Oncology Holdings was -29.40% per year. The lowest was -29.40% per year. And the median was -29.40% per year.

Back to Basics: PB Ratio


ALX Oncology Holdings PB Ratio Historical Data

The historical data trend for ALX Oncology Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings PB Ratio Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 7.99 2.40 1.75 3.92

ALX Oncology Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 0.77 1.45 1.17 3.92

Competitive Comparison of ALX Oncology Holdings's PB Ratio

For the Biotechnology subindustry, ALX Oncology Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALX Oncology Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's PB Ratio falls into.



ALX Oncology Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

ALX Oncology Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=16.61/3.798
=4.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


ALX Oncology Holdings  (NAS:ALXO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


ALX Oncology Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ALX Oncology Holdings (ALX Oncology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Executives
Shelly Pinto officer: VP, Finance and CAO 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia officer: Chief Financial Officer ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Sophia Randolph officer: Chief Medical Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons director, officer: President and CEO C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas director C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Jason Lettmann director, 10 percent owner C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lsv Associates, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Goodman Corey S director, 10 percent owner, other: Executive Chairman 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Rekha Hemrajani director 3928 POINT EDEN WAY, HAYWARD CA 94545
Venbio Global Strategic Fund, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Steffen Pietzke officer: VP Fin & Chief Acct Officer C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538

ALX Oncology Holdings (ALX Oncology Holdings) Headlines

From GuruFocus

ALX Oncology Appoints Scott Garland to its Board of Directors

By Value_Insider Value_Insider 11-29-2022